Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;29(6):305-11.

Hurthle cell tumours of the thyroid. Personal experience and review of the literature

Affiliations
Review

Hurthle cell tumours of the thyroid. Personal experience and review of the literature

A Barnabei et al. Acta Otorhinolaryngol Ital. 2009 Dec.

Abstract

Hurthle cell carcinoma represents about 5% of differentiated thyroid carcinomas. The prognosis of the malignant type of the tumour is still under debate as some Authors have reported that Hurthle cell adenoma occasionally behaves like Hurthle cell carcinoma. Aim of the present study was to evaluate previously reported data and personal experience on the clinical and pathological features of patients affected by Hurthle cell tumour that may predict disease progression and death. In the literature, factors potentially associated with decreased survival were identified and include: age, disease stage, tumour size, extra-glandular invasion, lymph node disease, distant metastases, extensive surgery, radioiodine treatment. From 1992 to 2003, the Authors identified 28 patients affected by Hurthle cell tumour, 9 with Hurthle cell adenoma and 19 with Hurthle cell carcinoma. Of these, 22 were females and 6 males. Mean age of patients affected by adenoma was 49.7 years (range 30-72) vs. 49.3 years (range 15-72) in Hurthle cell carcinoma patients. In all patients, total thyroidectomy was performed. At histology, 9 adenomas, 5 "minimally invasive" and 14 invasive carcinomas were found. Post-operatively, in Hurthle cell carcinoma patients, TNM staging showed 9 patients with stage I, 5 stage II, 4 stage III and one stage IVa (UICC, 2002). All invasive carcinomas underwent (131)I therapy (91-585 mCi). One Hurthle cell carcinoma patient received external beam radiotherapy. The mean follow-up period was 62 months (range 6-324). Relapse was not observed in any of the cases with adenoma. Only one Hurthle cell carcinoma patient showed distant lung metastases at 60 months' follow-up. In conclusion, Hurthle cell carcinoma was not found to present a more aggressive behaviour than follicular carcinoma, when risk factors, including extent of tumour invasion, were taken into account. None of the patients with Hurthle cell adenoma showed a relapse or death caused by the tumour.

Il carcinoma a cellule di Hurthle rappresenta circa il 5% di tutti i carcinomi differenziati della tiroide. La prognosi è ancora oggetto di discussione poiché alcuni Autori hanno riportato che l’adenoma a cellule di Hurthle occasionalmente può mostrare maggiore aggressività, paragonabile a quella del carcinoma. L’obiettivo di questo studio è la valutazione delle caratteristiche cliniche e patologiche predittive di peggior prognosi e di morte per questa neoplasia in un confronto tra i dati riportati in letteratura e la nostra esperienza. In letteratura, i parametri associati a riduzione della sopravvivenza (per tutti i pazienti) sono: età, stadio della malattia, dimensioni del tumore, invasione extraghiandolare, metastasi linfonodali, metastasi a distanza, estensione della chirurgia e terapia con radioiodio. Dal 1992 al 2003 sono stati identificati 28 pazienti affetti da neoplasia a cellule di Hurthle, 9 con adenoma e 19 con carcinoma; di questi 22 erano femmine e 6 maschi. L’età media dei pazienti affetti da adenoma era 49,7 anni (range 30-72) vs. 49,3 anni (range 15-72) dei pazienti affetti da carcinoma a cellule di Hurthle. Tutti i pazienti sono stati sottoposti ad intervento di tiroidectomia totale. L’esame istologico ha evidenziato 9 adenomi e 19 carcinomi di cui 5 minimamente invasivi. La classificazione postoperatoria secondo TNM (UICC, 2002) ha documentato 9 pazienti in stadio I, 5 in stadio II, 4 in stadio III ed 1 in stadio IV. Tutti i 14 carcinomi sono stati sottoposti a terapia con 131I (range 91-585 mCi). Un solo paziente è stato sottoposto a radioterapia esterna. Il follow-up medio è stato di 62 mesi (range 6-324). Nessuno dei pazienti con diagnosi istologica di adenoma ha presentato recidive di malattia. Solo un paziente affetto da carcinoma ha presentato metastasi polmonari dopo 60 mesi di follow-up. In conclusione, l’analisi della nostra casistica, condotta alla luce dei fattori prognostici e predittivi noti in letteratura mostra che il carcinoma a cellule di Hurthle non presenta maggiore aggressività rispetto al carcinoma follicolare, a parità di fattori di rischio incluso l’estensione locale della neoplasia. Nessun paziente affetto da adenoma a cellule di Hurthle ha presentato recidive o è morto a causa della neoplasia.

Keywords: Hurthle cell adenoma; Hurthle cell carcinoma; Thyroid.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bhattacharyya N. Survival and prognosis in Hurthle cell carcinoma of the thyroid gland. Arch Otolaryngol 2003;129:207-10. - PubMed
    1. Langhans T. Uber die epithelialen Formen der malignen Struma. Virchows Arch (Pathol Anat) 1907;189:69-152.
    1. Har-El G, Hadar T, Segal K, Levy R, Sidi J. Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy. Cancer 1986;57:1613-7. - PubMed
    1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Database report on 53856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48. - PubMed
    1. Chen H, Nicol TL, Zeiger MA, Dooley WC, Ladenson PW, Cooper DS, et al. Hurthle cell neoplasm of the thyroid: are there factors predictive of malignancy? Ann Surg 1998;227:542-6. - PMC - PubMed

Supplementary concepts

LinkOut - more resources